

PRESS RELEASE

EDEN BIODESIGN AND IMMUNOBIOLOGY (IMMBIO) DEVELOP NEXT GENERATION VACCINE FOR THE PREVENTION OF INFLUENZA

Liverpool, UK; 19th March 2007: Eden Biodesign Ltd, an innovative provider of development and manufacturing services for new medicines, announced today that it has been selected by ImmBio (Cambridge, UK), a leading biotechnology company developing the next generation of anti-infective vaccines, to provide a range of development and manufacturing services for their leading influenza vaccine programme. This targets both seasonal and pandemic flu, where manufacturing speed and flexibility is critical to meet unmet market needs.

Graham Clarke, CEO of ImmBio said: "Working with Eden Biodesign will allow us to rapidly advance the next generation influenza vaccine forward towards a Clinical Trial Application and is consistent with our aggressive timelines for bringing our viral lead product to the clinic. We are delighted for the development of our leading influenza programme to be managed by Eden Biodesign at their state of the art facility in Liverpool."

Dr Crawford Brown, CEO of Eden Biodesign commented: "We are very pleased to work with ImmBio on the further development of this promising vaccine and to accelerate its progress from research to the clinic. Eden Biodesign has the expertise in product development and manufacturing that is critical to ensure clinical and commercial success of this product."

Eden Biodesign is the operator of the National Biomanufacturing Centre (NBC) facility, part of the £34.25 million NBC project developed and owned by the NWDA¹ and funded by the NWDA, ERDF² and DTI³.

Ends


For further information contact:

Stéphanie Monfront, De Facto Communications Ltd +44 (0)20 7861 3838

Email s.monfront@defacto.com

Graham Clarke, ImmunoBiology Ltd +44 (0)1223 496117

Email graham.clarke@immunobiology.co.uk



Notes to editors:

Eden Biodesign

Eden Biodesign is a successful international biopharmaceutical development and manufacturing services business that provides 'state of the art' development and manufacturing services to biotech clients across Europe, the USA and Asia. It promises all clients a committed service plus the knowledge and expertise to guide clients through process development, manufacturing, regulatory and technology transfer challenges.

The company uses the principles of 'Good Science' at every step of biopharmaceutical development to design programmes and processes that deliver clinically and commercially valuable products, with an accomplished and attentive level of project management that clients need. For further information please visit www.edenbiodesign.com.


ImmBio

ImmBio is a vaccine company developing the next generation of anti-infective vaccines. The portfolio addresses areas of high unmet need, where the risk and consequence of infection are severe.

It is progressing a development portfolio of break-through products utilizing its HspC platform technology and ImmunoBodies technology. TB, supported by the Aeras Global TB Vaccine Foundation, in turn funded by the Bill & Melinda Gates Foundation is the lead bacterial product. Influenza, protective against both seasonal and pandemic strains, is the lead viral product. ImmBio is based at the Babraham Research Campus in Cambridge UK. For further information please visit www.immbio.com

The National Biomanufacturing Centre

The £34.25 million National Biomanufacturing Centre which was officially opened in November 2006, is a Government-funded initiative led by the Northwest Regional Development Agency (NWDA) additionally funded through the European Regional Development Fund (ERDF) and the Department of Trade and Industry (DTI) and aims to establish England's Northwest as one of the foremost biomanufacturing centres in Europe.



The centre provides the expertise and facilities to support new and existing biotechnology companies, offering product development services designed to fill in the skill and resource gaps that exist within these organisations. It also provides training in biomanufacturing and analytical sciences, delivering the skilled workforce required to expand the UK biopharmaceutical sector.

There is also an Access Fund of nearly £3 million funded by the Department of Trade and Industry and the European Regional Development Fund, which is available to qualifying small-to-medium companies and academic groups in the biotechnology sector to assist them in purchasing development and clinical manufacturing services from the Centre.

¹ Northwest Regional Development Agency (NWDA)

² European Regional Development Fund (ERDF)

³ Department of Trade and Industry (DTI)